comparemela.com
Home
Live Updates
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, ... : comparemela.com
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, ...
- Evaluation of IOS-1002, a LILRB1 (ILT2), LILRB2 (ILT4), KIR3DL1 targeting agent, in combination with KEYTRUDA® (pembrolizumab) as part of ongoing Phase 1a/b trial in advanced solid tumors
Related Keywords
United States ,
Zurich ,
Züsz ,
Switzerland ,
Schroder Adveq ,
Seanr Smith ,
Christoph Renner ,
Ludger Wess Ines Regina Buth ,
Merck Co Inc ,
Mission Biocapital ,
Merck Sharp Dohme ,
Zurich Area ,
Immunos Therapeutics ,
Chief Medical Officer ,
Chief Executive Officer ,
Merck Sharp ,
Samsara Biocapital ,
Lightspeed Venture Partners ,
Pfizer Ventures ,
Biomed Partners ,
Ludger Wess ,
Business ,
comparemela.com © 2020. All Rights Reserved.